European Pharmaceutical Review

AUGUST 21, 2023

Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56

Biopharma 98

Biopharma Marketing Sales Medicine 98

Clarivate

MAY 31, 2023

Pharma M&A activity was muted in 2022, coming in at its lowest level since 2013 – something of a surprise, given the looming patent cliff and pharma’s past reliance on M&A and biopartnering as a quick fix for revenues lost to generics and biosimilars competition. Of the biggest spenders in 2022, Merck/MSD opened its wallet the widest.

Pharma 52

Pharma Biopharma Medicine Healthcare 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

NOVEMBER 30, 2023

NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Clarivate

APRIL 18, 2024

Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. In 2019, UnitedHealth Group CEO David Wichmann indicated a plan to make Optum a $100B business by 2028, including by partnering with health systems for administrative services such as RCM and IT.

Retail 52

Retail Healthcare Healthcare Physicians 52

Pharmaceutical Technology

JUNE 20, 2023

At $48 a share for the South San Francisco,California-based biopharma, Lilly is paying a 40% premium on top of the 30-day average trading price. The deal, which is still subject to final regulatory approval, will see Lilly purchase all outstanding shares of DICE.

Prospecting 52

Prospecting Competition Biopharma Marketing 52

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics). In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52